Delray Beach, FL / ACCESSWIRE / September 15, 2014 / Thanks to a combination of market ingenuity and a strong scientific core, life science stalwart Pressure BioSciences (OTCQB:PBIO) continues to enjoy a resurgence of relevance as a veteran company. PBIO’s patented “pressure cycling technology, “or PCT”, is an up-and-coming, exciting, critically acclaimed resource for scientific sample preparation by its unique ability to offer unparalleled control of the actions of molecular cell and tissue samples through an intense pressure system. This process is used in applications as diverse as forensics, bio-marker discovery, and vaccine development.
Presently trading at $0.30 per share with an average volume of over 43K, PBIO remains accessible to investors looking to dive into the life sciences market with a long-term investment. Its underlying financials continue positive trends year after year. In 2014, product and service revenue in the first quarter for PBIO was up 82% from the same quarter in 2013, sitting comfortably at over $404,000, which also happened to be a new quarterly record for the Company. Sales of consumables also increased over 100% in that same time frame, with an overall jump in revenue of 9%.
With an increase to its potential sales market and the introduction of new technologies and improvements to its existing machines, PBIO has been posting similar gains each year. In June of this year, the company unveiled its latest PCT-based instrument, the Barozyme HT48, primarily used for enhanced preparation of proteins for mass spectrometry analysis. Taking sample preparation to the next level, the new machine will be able to process up to 48 samples at once and employs technology that can integrate with existing preparation techniques at biological research laboratories, making the Barozyme HT48 desirable for its adaptability.
Dr. Winston Patrick Kuo of the biotech IES Diagnostics, and former director of the LITT laboratory at Harvard Medical School, called PBIO’s PCT systems “among the top sample preparations of choice,” adding that the quality of sample preparation was always vital in his research, and that the new Barozyme HT48 represents the epitome of PBIO’s pressure cycling technologies.
While the experience in Dr. Kuo’s words is invaluable, it represents only a small fraction of the potential behind sample prep, mass spectrometry, and the forensics tools markets. The forensics tools and products market is expected to reach nearly $18 billion in 2019, while sample prep for Genomics, Proteomics, and Lipidomics will be $8.4 billion in just 2016, and mass spectrometry and next generation sequencing will all see vast increases as well. Among other companies creating similar tools for life sciences include Thermo Fisher (TMO) and Hologic (HOLX), a company specializing in mammography and women’s health molecular diagnostic products, whose revenues increased significantly last quarter.
Becton Dickinson & Co. (BDX), a medical technology company whose products are used worldwide in clinical laboratories and healthcare institutions, can be used as a measuring stick for the success of the industry. Over the last five years, the company’s revenue and net income experienced consistent, unflinching growth. The trend bodes well for companies like PBIO, because it indicates not only the growing demands across the entire medical community for enhanced diagnostic tools, but also the sheer progress made by scientific research in that new technologies are turning over all the time, and the institutions that intend to remain on the forefront of treatment and research must continue to employ the latest and best machines in order to do so.
Pressure BioSciences estimates that there are up to 16,000 labs worldwide doing MS protein analyses that would benefit from the advanced technologies of the Barozyme HT48. In addition, the large number of forensics labs involved in rape kit testing would also be greatly enhanced by PBIO’s technology because it would allow those labs to process samples at a much faster rate while increasing testing efficiency, which has the potential to both expedite and improve criminal justice. PBIO views these labs as their future customer base and intends to increase revenue through product sales in these areas over the next several years.
The many avenues that can be explored by Pressure BioSciences in the coming years are vast in number. With technologies constantly improving, PBIO is at the forefront of several fast-growing markets like genomics and forensic tools and products. A built-in customer base of laboratories and clinical institutions that will require PBIO’s technologies in order to stay competitive means that sustained long-term growth is inevitable. Investors seeking to buy-in on a life sciences industry that is one of the few out there still booming, need look no further than PBIO.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
To begin your research on PressureBioSciences
For full disclaimer/disclosure pertaining to this release please read: http://tomorrowsbluechips.com/disclaimer/
Disclaimer:
This article includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward- looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contact:
http://tomorrowsbluechips.com/contact-us/
SOURCE: TomorrowsBluechips